112 related articles for article (PubMed ID: 6455775)
1. Enzymatic properties of plasmins converted from acid-treated and native Glu- and Lys-plasminogens by urokinase.
Takada A; Takada Y
Thromb Res; 1981 Mar; 21(6):593-601. PubMed ID: 6455775
[No Abstract] [Full Text] [Related]
2. Conversion of proteolytically modified form (Lys-form) of human plasminogen to plasmin by urokinase in the presence of tranexamic acid.
Takada A; Takada Y
Thromb Res; 1981 Aug 15-Sep 1; 23(4-5):411-9. PubMed ID: 6459659
[No Abstract] [Full Text] [Related]
3. Conversion of Glu-plasminogen to plasmin by urokinase in the presence of tranexamic acid.
Takada A; Takada Y
Thromb Res; 1981 May; 22(4):437-43. PubMed ID: 6457415
[No Abstract] [Full Text] [Related]
4. Activation pathway of glu-plasminogen to Lys-plasmin by urokinase.
Takada A; Takada Y
Thromb Res; 1982 Sep; 27(6):671-7. PubMed ID: 6129717
[TBL] [Abstract][Full Text] [Related]
5. Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.
Suenson E; Thorsen S
Biochem J; 1981 Sep; 197(3):619-28. PubMed ID: 6459779
[TBL] [Abstract][Full Text] [Related]
6. Effects of tranexamic acid on the conversion of Glu-plasminogen I and II to its Lys-forms.
Takada A; Takada Y
Thromb Res; 1985 Oct; 40(2):171-9. PubMed ID: 2933845
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic states in a patient with congenital deficiency of alpha 2-plasmin inhibitor.
Aoki N; Sakata Y; Matsuda M; Tateno K
Blood; 1980 Mar; 55(3):483-8. PubMed ID: 7357079
[No Abstract] [Full Text] [Related]
8. Urokinase-catalysed plasminogen activation. Effects of ligands binding to the AH-site of plasminogen.
Christensen U
Biochim Biophys Acta; 1988 Nov; 957(2):258-65. PubMed ID: 3191143
[TBL] [Abstract][Full Text] [Related]
9. Zymogen-activation kinetics. Modulatory effects of trans-4-(aminomethyl)cyclohexane-1-carboxylic acid and poly-D-lysine on plasminogen activation.
Petersen LC; Brender J; Suenson E
Biochem J; 1985 Jan; 225(1):149-58. PubMed ID: 2579638
[TBL] [Abstract][Full Text] [Related]
10. Effects of tranexamic acid, cis-AMCHA, and 6-aminohexanoic acid on the activation rate of plasminogen by urokinase in the presence of clot.
Takada A; Ohashi H; Matsuda H; Takada Y
Thromb Res; 1979; 14(6):915-23. PubMed ID: 473126
[No Abstract] [Full Text] [Related]
11. Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis.
Bangert K; Thorsen S
Thromb Haemost; 2000 Aug; 84(2):299-306. PubMed ID: 10959704
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the activation of Glu-plasminogen by urokinase in the simultaneous presence of tranexamic acid or fibrin.
Takada A; Sugawara Y; Takada Y
Haemostasis; 1989; 19(1):26-31. PubMed ID: 2920977
[TBL] [Abstract][Full Text] [Related]
13. Interaction of plasmin with alpha 2-macroglobulin and alpha 2-antiplasmin in the presence and absence of tranexamic acid.
Takada A; Takada Y
Thromb Res; 1980 Apr 1-15; 18(1-2):237-46. PubMed ID: 6157220
[No Abstract] [Full Text] [Related]
14. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
Thorsen S; Müllertz S; Suenson E; Kok P
Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
[TBL] [Abstract][Full Text] [Related]
15. Influence of dextran sulfate and tranexamic acid on the activation of plasminogen by urokinase.
Takada Y; Takada A
Thromb Res; 1979; 16(5-6):865-9. PubMed ID: 160629
[No Abstract] [Full Text] [Related]
16. Physical and chemical properties of the NH2-terminal glutamic acid and lysine forms of human plasminogen and their derived plasmins with an NH2-terminal lysine heavy (A) chain.
Robbins KC; Boreisha IG; Arzadon L; Summaria L
J Biol Chem; 1975 Jun; 250(11):4044-7. PubMed ID: 123921
[TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of the affinity chromatography forms of human Glu- and Lys-plasminogens and plasmins.
Summaria L; Spitz F; Arzadon L; Boreisha IG; Robbins KC
J Biol Chem; 1976 Jun; 251(12):3693-9. PubMed ID: 132440
[TBL] [Abstract][Full Text] [Related]
18. Effects of tranexamic acid on fibrinolysis, fibrinogenolysis and amidolysis.
Takada A; Makino Y; Takada Y
Thromb Res; 1986 Apr; 42(1):39-47. PubMed ID: 3705023
[TBL] [Abstract][Full Text] [Related]
19. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system.
Ries M; Zenker M; Gaffney PJ
Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278
[TBL] [Abstract][Full Text] [Related]
20. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator.
Wu G; Mazzitelli BA; Quek AJ; Veldman MJ; Conroy PJ; Caradoc-Davies TT; Ooms LM; Tuck KL; Schoenecker JG; Whisstock JC; Law RHP
Blood Adv; 2019 Mar; 3(5):729-733. PubMed ID: 30814058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
